868706-61-0

Basic information

• Product Name: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-(4-amino-3-methyl-5-nitro-benzyl)-2-[4-(4-methyl-piperazin-1-yl)piperidin-1-yl]-2-oxo-ethyl ester
• Synonyms: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-(4-amino-3-methyl-5-nitro-benzyl)-2-[4-(4-methyl-piperazin-1-yl)piperidin-1-yl]-2-oxo-ethyl ester
• CAS NO: 868706-61-0
• Molecular Weight: 676.816
• Mol File: 868706-61-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-(4-amino-3-methyl-5-nitro-benzyl)-2-[4-(4-methyl-piperazin-1-yl)piperidin-1-yl]-2-oxo-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-(4-amino-3-methyl-5-nitro-benzyl)-2-[4-(4-methyl-piperazin-1-yl)piperidin-1-yl]-2-oxo-ethyl ester(868706-61-0)
• EPA Substance Registry System: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-(4-amino-3-methyl-5-nitro-benzyl)-2-[4-(4-methyl-piperazin-1-yl)piperidin-1-yl]-2-oxo-ethyl ester(868706-61-0)

Safety Data

• Hazardous Substances Data: 868706-61-0(Hazardous Substances Data)

Upstream product

• 53617-36-0 1-methyl-4-(piperidin-4-yl)piperazine 

Downstream Products

• 868706-62-1 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-(3,4-diamino-5-methyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)piperidin-1-yl]-2-oxo-ethyl ester 

Relevant articles and documents

Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP antagonists of general formula wherein A, X, Q and R1 to R3 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, their use and processes for preparing them.